First Cases for Aorfix™ in Brazil
London, UK, 22 May 2007 - Lombard Medical Technologies PLC (“Lombard Medical”) today announces that its Aorfix™ endovascular stent graft has been successfully implanted for the first time in Brazil, bringing the total number of countries in which Aorfix™ has been implanted to eighteen.
Brazil is the fourth largest market in the world for endovascular abdominal aortic aneurysm repair (“EVAR”) with between 1,800 and 2,000 EVAR procedures performed each year. There are more than 20 million people over 65 years of age in Brazil with an estimated number of abdominal aortic aneurysms (“AAA”) between 300,000 and 400,000 each year. This market is expected to increase significantly over the next several years with increased patient awareness and improved screening.
Lombard Medical sells Aorfix™ in Brazil through its local distributor ABBMED do Brazil.
Alistair Taylor, Executive Chairman, said:
“We are delighted to have entered what is potentially a major market for EVAR with the already large elderly population expected to almost double by 2030.”
Enquiries:
Lombard Medical Technologies PLC Tel: 01235 750 800
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer
Tim Hall, Finance Director
Financial Dynamics Tel: 020 7831 3113
John Gilbert
Notes to editors
About Lombard Medical
Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment of vascular disease. The Company’s lead product, Aorfix™, is a stent graft for the treatment of aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Abdominal and thoracic aortic aneurysms are the 13th largest cause of death in the US and the market is estimated to be worth approximately US$2 billion by 2010. Aorfix™ is currently being commercialised in the EU, with US clinical trials having commenced during 2006. The Company’s Polymer Coatings Division primarily develops polymer coatings for use in drug eluting stents and has a number of research collaborations developing novel products for this $6bn market.
The Company, headquartered in Oxfordshire, with operations in Yorkshire and Boston, USA, employs over 90 people.
Further background on the Company can be found at www.lombardmedical.com.